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Bacterial endotoxins and antigen-antibody aggregates activate complement, 
accelerate blood coagulation, and are implicated in intravascular blood clotting 
(1-7). That their effect on blood coagulation proceeds through the activation 
of the complement system has been suspected but has never been shown. We 
have found that these and other complement-activating  materials initiate blood 
coagulation through a complement-mediated pathway. 
The  demonstration of  a  coagulation abnormality in blood of  a  rabbit de- 
ficient in the sixth component of complement (C6) and its correction with puri- 
fied  C6  has  provided direct  evidence for  the  involvement of  complement in 
normal hemostasis (8). The experiments reported here indicate that activation 
of complement can initiate blood coagulation and suggest an important role for 
complement in pathologic blood coagulation. 
Materials and Methods 
Inu]in, chemically pure  (Pfanstiehl Chemical Corp., Waukegan, Ill.), was dissolved at a 
concentration  of 20  mg/ml in barbital-buffered saline  (0.005 M sodium barbital,  0.145 
NaC1, 0.0005 M MgC12, 0.00015 ~  MgC12, pH 7.5) at 60°C. A precipitate formed when the 
solution was cooled to room temperature  and was partially removed by centrifugation  at 
1000 g for 5-10 min in a Serofuge (Clay-Adams, Inc., New York). 0.1 ml aliquots of the 20 
mg/ml solution were mixed with 1 ml of rabbit blood for determination of the effect on pro- 
thrombin consumption; 0.05 ml aliquots were used for determining the effect on clotting 
times. 
Salmonella endotoxin, obtained from Dr.  Otto Lilderitz of the  Max-Planck-Institut far 
Immunbiologie, Freiburg,  Germany, was dissolved in distilled water  at a concentration  of 
2 mg/ml. 20/zl was mixed with 1 ml of blood. Staphylococcal protein A, obtained from Dr. 
Gunnemar St£1enheim, The Wallenberg Laboratory,  Uppsala, Sweden, was dissolved at a 
concentration of 1.3 mg/ml. 0.1 ml aliquots were mixed with 1 ml of blood. 
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Gamma  globulin  (Cohn  fraction  II,  a  gift  of Lederle  Laboratories  Division,  American 
Cyanamid  Co., Pearl River, N.Y.)  was dissolved in barbital-buffered saline at  a  concentra- 
tion of 10 mg/ml and subjected to centrifugation at 170,000  g (average) for 90 min in a SW-50 
swinging bucket  rotor  in  a  Spinco L-2  ultracentrifuge  (Beckman  Instruments,  Palo  Alto, 
Calif.). The top third of the supernatant was removed and an aliquot heated at 60°C  for  10 
min. An unheated aliquot was used as the control. Aliquots of 0.2 ml were mixed with 1  ml 
of blood. Kaolin, NF (J.T. Baker Chemical Co., Philipsburg, N.J.) was suspended in barbital- 
lmffered saline at a concentration of 20 mg/ml and was used in 0.1 ml aliquots for prothrombin 
consumption experiments and  in  0.05  ml  aliquots  for  clotting  time  experiments,  isolated 
rabbit and human C6 was prepared as previously described (9). It was used in 0.1 ml aliquots 
at a concentration of 25 ~g/ml. 
Rabbit blood was obtained from the hind leg vein using a  No.  19 small vein infusion set 
(McGaw Laboratories Inc.,  Glendale,  Calif.)  and  disposable polypropylene syringes  (Sher- 
wood  Medical Industries Inc.,  Deland,  Fla.).  A  two-syringe technique was used  and  great 
care was taken to avoid contamination with tissue juices. 1 ml aliquots of freshly drawn blood 
TABLE  I 
I'~ect of Kaolin and [rodin on Clotting  Times of Normal and C6-Deficlent  Ra~blt 
Blood* 
Type of blood  Material added  Clotting time 
Normal  Kaolin  5-10 
Normal  Inulin  20 
Normal  Buffer  60 
C6 deficient  Kaolin  5-10 
C6 deficient  Inulin  230 
C6 deficient  Buffer  220 
* Clotting times were performed in polypropylene tubes at 25°C. Kaolin and inulin were 
used in similar quantities. For additional details see Materials and Methods. 
were  added  immediately  to  duplicate  12  X  75-mm  polypropylene tubes  (Falcon  Plastics, 
Oxnard, Calif.) containing the substance to be tested. Mixing was achieved by gentle tapping. 
Clotting times were determined  at  25°C  using a  serial,  three-tube technique  (8).  For pro- 
thrombin consumption determinations, tubes were incubated at 37°C for the indicated time. 
The clotting process was then stopped by removal of the tubes to an ice water bath and the 
addition of 0.04 ml of 0.5 M citrate lmffer, pH 5.0.  The serum was then assayed for residual 
prothrombin (8).  Results are expressed as the average values from duplicate incubation mix- 
tures. 
RESULTS 
Inulin,  as compared to buffer, shortened clotting times (Table I) and mark- 
edly accelerated prothrombin consumption in normal rabbit blood. The latter 
effect was apparent after 10 rain incubation  at 37°C (see Table If). No such 
dot-promoting effect of inulin could be  demonstrated  in  C6-deficient blood. 
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TABLE  II 
The Accderation of Prothromgin Consumption by Complement-Activating Materials* 
Material tested  Type of blood  Incubation  Prothrombin  time  consumed 
rain  % 
Inulin  Normal rabbit  10  >99 
Buffer  Normal rabbit  10  0 
Inulin  C6-deficient rabbit  10  0 
Buffer  C6-defieient rabbit  10  0 
Inulin  C6-deficient rabbit  60  22 
Buffer  C6-deficient rabbit  60  33 
Inulin and C6  C6-deficient rabbit  22  50 
Buffer and C6  C6-defieient rabbit  22  0 
Endotoxin  Normal rabbit  10  94 
dH20  Normal rabbit  10  0 
Endotoxin  C6-deficient rabbit  10  0 
dH20  C6-deficient rabbit  l0  0 
Endotoxin  C6-deficient rabbit  60  16 
Endotoxin  C6-deficient rabbit  60  10 
Staphylococcal 
Protein A  Normal rabbit  12  72 
Buffer  Normal rabbit  12  0 
Staphylococcal 
Protein A  C6-deficient rabbit  12  0 
Buffer  C6-deficient rabbit  12  0 
Staphylococcal 
Protein A  C6-deficient rabbit  60  81 
Buffer  C6-deficient rabbit  60  59 
Heat-aggregated 3'-globulin  Normal rabbit  10  73 
Unheated "g-globulin  Normal rabbit  10  0 
Heat-aggregated 3'-globulin  C6-deficient rabbit  10  0 
Unheated 3'-globulin  C6-deficient rabbit  10  0 
Heat-aggregated 3,-globulin  C6-deficient rabbit  70  20 
Unheated 3,-globulin  C6-deficient rabbit  70  38 
Kaolin  C6-deficient rabbit  10  >99 
Buffer  C6-deficient rabbit  10  0 
* Incubations were carried out at 37°C  in polypropylene tubes. For additional details see 
Materials and Methods. 
tended  the  incubation  time  sufficiently  long  to  allow  some  prothrombin  con- 
sumption to occur in the C6-deficient blood mixed  with buffer (60 min). After 
this prolonged incubation, a mild anticoagulant effect of inulin became apparent 
and  less  prothrombin  was  consumed  in  the  inulin-containing  tubes  than  in 1604  BLOOD  COAGULATION INITIATION 
those to which buffer had been added.  C6-deficient blood could be made sensi- 
tive to the clot-promoting action of inulin by the addition  of small amounts 
(2.5 #g/ml) of isolated (;6 and extending the incubation period from 10 to 22 
min (Table II). The normal concentration of C6 is 25-50 ~g/ml of blood. 
Endotoxin and staphylococcal protein A, the two bacterial products tested, 
both  accelerated prothrombin  consumption in  normal  rabbit  blood but  had 
little effect on C6-deficient blood. After 10 or 12 min incubation, respectively, 
greater than  70%  of prothrombin was consumed in normal blood mixed with 
these  substances,  whereas  none was  consumed  in  C6-deficient  blood.  Even 
after prolonged incubation  (60 rain)  only slight  acceleration of prothrombin 
consumption could be detected in the deficient blood. 
Human 3,-globulin, aggregated by heat,  also  accelerated prothrombin con- 
sumption  in  normal  rabbit  blood,  but  failed  to  do  so in  that  from the  C6- 
deficient animal.  After prolonged incubation less  prothrombin was  consumed 
in C6-deficient blood mixed with heat-aggregated 3,-globulin than that mixed 
with the unheated 3,-globulin control. 
These findings demonstrate that blood coagulation initiation by these com- 
plement activators requires an intact complement system. Kaolin, on the other 
hand,  markedly  accelerated clotting  times  and prothrombin  consumption in 
C6-deficient blood.  We have previously shown  that  C6-deficient blood clots 
much more rapidly in glass than in plastic tubes (8). Thus, these classic surface 
activators of Hageman factor (factor XII)  can clearly initiate clotting in the 
absence of an intact complement system. 
DISCUSSION 
The classical mechanism of complement activation involves the interaction 
of C1  with immunoglobulin aggregates, followed by the formation of the  C3 
convertase (C4--fi) and subsequent initiation of the C3-9 sequence. Recently, 
an alternate pathway of complement activation has been defined which initiates 
the complement sequence at C3, bypassing the earlier components (10-13). A 
variety  of  plant  and  bacterial  polysaccharides,  as  well  as  immunoglobulin 
aggregates, can activate this mechanism. Inulin appears to activate complement 
exclusively by this  mechanism  (13)  and  endotoxin largely so  (1).  The com- 
plement-activating properties of staphylococcal protein A depend on complex 
formation with immunoglobulins (14), and therefore it probably can activate 
both pathways. 
The efficacy of inulin in promoting clotting in normal but not C6-deficient 
rabbit blood indicates that activation of the alternate pathway of complement 
activation can initiate blood coagulation. It is not yet clear if the classic mech- 
anism of complement activation is also effective. 
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mediated pathway is summarized in Fig. 1. Initiation of blood coagulation by 
the surface activators, kaolin and glass, can proceed in the absence of C6. How- 
ever, the complement  activators tested (endotoxin,  staphylococcal  protein A, 
immunoglobulin aggregates, and inulin) have little or no effect on clotting un- 
less the complement system is intact. Thus, surface activation and complement 
activation would appear to represent two distinct mechanisms for the initiation 
of blood coagulation. 
The precise mechanism(s)  of interaction between the complement and blood 
coagulation  systems is (are) uncertain. Antigen-antibody complexes have been 
reported to activate Hageman factor (15, 16)  and it has been suggested that 
endotoxin  might also do this (17, 18). Both antigen-antibody complexes and 
endotoxin  increase  platelet factor III activity (19). Whether either of these 
actions are complement mediated is unclear at present. However, it is apparent 
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FIG. 1. A proposed concept of the initiation of blood coagulation by the complement- 
mediated pathway. 
that though these agents may have multiple effects on the coagulation system 
their predominant action is complement mediated. 
The Sanarelli-Shwartzman  reaction  has served  as  the classical laboratory 
model for clinical intravascular coagulation of the type associated with bacterial 
sepsis (6). It now appears that the in vitro clot-promoting qualities of endotoxin 
are largely  dependent on the complement-mediated  pathway; it is probable 
that  this  type  of  intravascular coagulation  is  at  least  in  part  complement 
mediated. Several diseases characterized by the presence of circulating immuno- 
globulin  complexes display fibrin(ogen),  complement,  and 3,-globulin at  the 
site of vascular or renal lesions (20-23). Complement-initiated  coagulation may 
also play a  role  in  the pathogenesis  of  these  disorders.  The mechanism  for 
complement-mediated  acceleration of blood coagulation and the importance of 
this mechanism in the pathogenesis of intravascular clotting is under investiga- 
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SUMMARY 
A  variety  of  complement-activating  substances,  including  inulin,  immuno- 
globulin  aggregates,  bacterial  endotoxins,  and  staphylococcal protein  A, were 
found to initiate  blood coagulation through  a  complement-mediated  pathway. 
These  substances  markedly  accelerated  blood  coagulation  in  normal  rabbit 
blood. That this clot-promoting activity requires an intact complement system 
was demonstrated by an almost total lack of effect on blood from rabbits with 
an  inherited  deficiency  of  the  sixth  component  of  complement  (C6).  Small 
amounts of isolated  C6 conferred to C6-deficient blood the  ability  to respond 
with  accelerated  coagulation  upon  activation  of  the  complement  system.  In 
addition,  it  was  determined  that  activation  of  complement  through  the  pre- 
viously described  C3  activator  system  resulted  in  the  initiation  of blood  co- 
agulation. The participation of C1, C2, and C4 was not necessary. 
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